Jasper Therapeutics (Nasdaq:JSPR) - 주가, 뉴스 및 분석

JSPR 주식 개요

임상 단계의 생명공학 회사인 재스퍼 테라퓨틱스는 조혈 줄기세포 이식 및 유전자 치료를 위한 치료제를 개발하는 회사입니다. 자세한 내용

JSPR 기본 분석
눈송이 점수
가치 평가	1/6
미래 성장	2/6
과거 실적	0/6
재무 상태	6/6
배당금	0/6

보상

수익은 연간 72.57% 증가할 것으로 예상됩니다.

위험 분석

수익이 1백만 달러 미만인 경우 ( $0 )

수익은 향후 3년간 연평균 16.4% 씩 감소할 것으로 예상됩니다.

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.

지난 1년 동안 주주가 희석되었습니다.

+ 1 더 많은 위험

Jasper Therapeutics, Inc. 경쟁사

Q32 Bio

NasdaqGM:QTTB

US$299.0m

AC Immune

NasdaqGM:ACIU

US$334.4m

AVITA Medical

NasdaqCM:RCEL

US$350.2m

Design Therapeutics

NasdaqGS:DSGN

US$318.2m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Jasper Therapeutics
과거 주가
현재 주가	US$22.73
52주 최고치	US$31.01
52주 최저치	US$4.00
베타	2.2
11개월 변경	16.27%
3개월 변경 사항	12.25%
1년 변경 사항	249.32%
33년 변화	-71.01%
5년 변화	n/a
IPO 이후 변화	-76.85%

최근 뉴스 및 업데이트

Jasper Therapeutics: Briquilimab's Potential In Chronic Urticaria And Asthma

Nov 18

We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

Aug 30

Recent updates

Jasper Therapeutics: Briquilimab's Potential In Chronic Urticaria And Asthma

Nov 18

We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

Aug 30

We Think Jasper Therapeutics (NASDAQ:JSPR) Needs To Drive Business Growth Carefully

Jan 23

Companies Like Jasper Therapeutics (NASDAQ:JSPR) Are In A Position To Invest In Growth

Jul 31

Jasper Therapeutics: Advancing Cures With HSC Transplants And Safer Prior Conditioning

Nov 28

We Think Jasper Therapeutics (NASDAQ:JSPR) Can Afford To Drive Business Growth

Nov 23

주주 수익률

	JSPR	US Biotechs	US 마켓
7D	13.5%	4.0%	2.2%
1Y	249.3%	18.3%	32.6%

수익률 대 산업: JSPR 지난 1년 동안 18.3 %를 반환한 US Biotechs 산업을 초과했습니다.

수익률 대 시장: JSPR 지난 1년 동안 32.6 %를 반환한 US 시장을 초과했습니다.

가격 변동성

Is JSPR's price volatile compared to industry and market?
JSPR volatility
JSPR Average Weekly Movement	11.2%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

안정적인 주가: JSPR 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: JSPR 의 주간 변동성( 11% )은 지난 1년 동안 안정적이었지만 여전히 US 의 75%보다 높습니다. 주식.

회사 소개

설립	직원	CEO	웹사이트
n/a	45	Ron Martell	www.jaspertherapeutics.com/

임상 단계의 생명공학 회사인 재스퍼 테라퓨틱스는 조혈 줄기세포 이식 및 유전자 치료를 위한 치료제를 개발하는 회사입니다. 회사의 주요 제품 후보는 동종 줄기 세포 치료 또는 줄기 세포 유전자 치료를 받기 전에 환자의 골수에서 조혈 줄기 세포를 제거하는 새로운 치료 항체로 임상 개발 중인 브리퀼리맙입니다. 만성 자연 두드러기, 중저위험 골수형성이상증후군, 조혈모세포 이식을 위한 조절 요법 등의 질환 치료제의 개발 및 상용화에 주력하고 있습니다.

Jasper Therapeutics, Inc. 기본 사항 요약

Jasper Therapeutics 의 수익과 매출은 시가총액과 어떻게 비교하나요?
JSPR 기본 통계
시가총액	US$330.78m
수익(TTM)	-US$63.53m
수익(TTM)	n/a

0.0x

P/S 비율

-5.4x

P/E 비율

JSPR 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
JSPR 손익 계산서(TTM)
수익	US$0
수익 비용	US$0
총 이익	US$0
기타 비용	US$63.53m
수익	-US$63.53m

최근 보고된 수익

Sep 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-4.23
총 마진	0.00%
순이익 마진	0.00%
부채/자본 비율	0%

JSPR 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

JSPR 주식 개요

보상

위험 분석

Jasper Therapeutics, Inc. 경쟁사

NasdaqGM:QTTB

US$299.0m

NasdaqGM:ACIU

US$334.4m

NasdaqCM:RCEL

US$350.2m

NasdaqGS:DSGN

US$318.2m

가격 내역 및 성능

최근 뉴스 및 업데이트

Jasper Therapeutics: Briquilimab's Potential In Chronic Urticaria And Asthma

Jasper Therapeutics, Inc. Reports Positive Data from Spotlight Study of Briquilimab in Chronic Inducible Urticaria

New minor risk - Share price stability

We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

Price target increased by 7.7% to US$69.13

Jasper Therapeutics, Inc. Announces Board Changes

Recent updates

Jasper Therapeutics: Briquilimab's Potential In Chronic Urticaria And Asthma

Jasper Therapeutics, Inc. Reports Positive Data from Spotlight Study of Briquilimab in Chronic Inducible Urticaria

New minor risk - Share price stability

We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

Price target increased by 7.7% to US$69.13

Jasper Therapeutics, Inc. Announces Board Changes

Jasper Therapeutics, Inc. to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024

Asper Therapeutics, Inc Announces the Expansion of its Mast Cell Development Portfolio with Phase 1b/2a Study Evaluating Briquilimab in Asthma Patients

Jasper Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Jasper Therapeutics, Inc. Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria

Jasper Therapeutics, Inc. Announces Additional Positive Phase 1b/2a Data on Briquilimab as A Conditioning Agent in the Treatment of Fanconi Anemia

Jasper Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50.505 million.

New major risk - Share price stability

Jasper Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $50.505 million.

We Think Jasper Therapeutics (NASDAQ:JSPR) Needs To Drive Business Growth Carefully

Price target decreased by 11% to US$61.25

Jasper Therapeutics Announces Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement of Common Stock for Continued Listing on the Nasdaq Capital Market

Jasper Therapeutics, Inc. Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation At ASH 2023

Jasper Therapeutics, Inc. Announces First Patient Dosed in Phase 1B/2A Clinical Study of Briquilimab in Chronic Spontaneous Urticaria

Less than half of directors are independent

Jasper Therapeutics Announces Oral Presentation of Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant at ASH 2023

Jasper Therapeutics, Inc. Announces Board Changes

Jasper Therapeutics Receives Written Notice from Nasdaq Regarding Minimum $1.00 Per Share Requirement

Jasper Therapeutics, Inc. Announces Chief Financial Officer Changes

Price target increased by 9.8% to US$6.88

New major risk - Revenue and earnings growth

Jasper Therapeutics Strengthens Management Team with Key Appointments

Companies Like Jasper Therapeutics (NASDAQ:JSPR) Are In A Position To Invest In Growth

Jasper Therapeutics, Inc. Announces First Patient Dosed in A Phase 1 Trial of Briquilimab in Lower-Risk Myelodysplastic Syndrome

Jasper Therapeutics, Inc. Appoints Scott Brun to Its Board of Directors

CFO, COO & Corporate Secretary notifies of intention to sell stock

Jasper Therapeutics, Inc. Announces Appointment of Edwin J. Tucker as Chief Medical Officer

Jasper Therapeutics, Inc. Announces Appointment of Stephen J. Galli to Scientific Advisory Board

Jasper Therapeutics, Inc. Appoints Vishal Kapoor as Class I Director

Price target increased by 11% to US$5.97

We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

Price target decreased by 9.0% to US$7.10

Jasper Therapeutics, Inc. Announces New Positive Briquilimab Data to Be Presented at the 2023 Tandem Meetings

Jasper Therapeutics, Inc. Announces Development Prioritization of Briquilimab in Chronic Diseases

Jasper Therapeutics Announces European Union Orphan Drug Designation for Briquilimab as A Conditioning Treatment for Patients Prior to Receiving A Stem Cell Transplant

Jasper Therapeutics, Inc. Announces Positive Clinical Data from A Phase I/Ii Trial of Briquilimab as A Conditioning Treatment in Sickle Cell Disease and Beta Thalassemia

Price target decreased to US$7.80

High number of new directors

Price target decreased to US$12.00

Jasper Therapeutics Receives Written Notice from Nasdaq

Jasper Therapeutics (NASDAQ:JSPR) Will Have To Spend Its Cash Wisely

Jasper Therapeutics Announces Positive Clinical Data from Investigator Sponsored Study of JSP191 Conditioning in Fanconi Anemia Patients at IEWP Annual Meeting

Jasper Therapeutics Announces FDA Fast Track Designation for JSP191, A Novel Monoclonal Antibody Targeting CD117, in the Treatment of Patients with Severe Combined Immunodeficiency (SCID) Undergoing Allogeneic Hematopoietic Stem Cell Transplant

Price target decreased to US$12.25

Jasper Therapeutics GAAP EPS of -$0.29 beats by $0.02

Non-Executive Chairperson of the Board notifies of intention to sell stock

Is Jasper Therapeutics (NASDAQ:JSPR) In A Good Position To Invest In Growth?

Jasper Therapeutics Announces Treatment of First Patient in Study of JSP191 Conditioning in Patients with Fanconi Anemia

Jasper Therapeutics, Inc. Announces Development of Novel Curative Therapies Based on the Biology of the Hematopoietic Stem Cell

Jasper Therapeutics, Inc., Annual General Meeting, Jun 23, 2022

High number of new directors

Jasper Therapeutics, Inc. Announces Updated Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation

High number of new directors

Jasper Therapeutics, Inc. Announces Executive Changes